Articles from XCath

XCath, a medical device company pioneering neuro-endovascular surgical robotics, announced today that it has secured $30 million in Series C funding, bringing the total raised since the company’s inception to $92 million. The round was co-led by Crescent Enterprises and by Dr. Fred Moll, Chairman of the XCath Board of Directors. These latest funds will support XCath’s ongoing efforts to bring the world’s first commercially-practical endovascular robot to the market and to perform a clinical telerobotic mechanical thrombectomy.

XCath, a medical device company dedicated to pioneering neuro-endovascular surgical robotics, announced today the successful first-in-human use of its EVR robotic system to treat three patients with complex brain aneurysms. The landmark procedures were performed at The Panama Clinic in Panama City, Panama, led by Vitor Mendes Pereira, M.D., with local principal investigator Dr. Anastasio Ameijeiras Sibauste. It marks the second time in history that a surgical robot has been used in an intracranial neurovascular intervention. With these procedures, XCath’s EVR becomes the only endovascular robotic system currently in development that has achieved intracranial navigation or neurointerventional treatment. It is also the world’s first triaxial neurovascular robot to perform treatment.

XCath, a medical device company dedicated to expanding endovascular treatment modalities through its telerobotic systems, announced today the incorporation of AI-driven simulation powered by NVIDIA Isaac for Healthcare into XCath’s autonomous robotic system. The new, advanced capabilities uniquely position XCath’s platform to deliver the highest standard of care for stroke and other complex vascular conditions to patients globally.

XCath, an early-stage medical device company dedicated to expanding endovascular treatment modalities through its smart steerable guidewires and robotic systems, successfully completed a first-of-its-kind live telerobotic trial for stroke treatment between Abu Dhabi and South Korea at Abu Dhabi Global Healthcare Week (ADGHW).

XCath, an early-stage medical device company dedicated to expanding endovascular treatment modalities through its smart steerable guidewires and robotic systems, will exhibit its technology through innovation sessions at Abu Dhabi Global Healthcare Week (ADGHW) hosted by the Abu Dhabi Department of Health (DoH). The demonstration will include a live telerobotic trial procedure between Abu Dhabi and South Korea on May 15th at 11:00 am GST, demonstrating the XCath platform’s potential to support remote minimally invasive procedures for the management of acute neurovascular conditions. Dr. Vitor Mendes Pereira, Director of Endovascular Research and Innovation at St. Michael’s Hospital in Toronto, Canada, will perform the live trial demonstration.

XCath, an early-stage medical device company dedicated to expanding endovascular treatment modalities through its robotic systems and steerable guidewires, presented at the annual SLICE Next Frontiers Conference hosted by Dr. Vincent Costalat and Master and Fellow. The event, which took place from April 3-4 and was broadcasted live from the Montpellier Centre Hospitalier Universitaire in France, was designed to address the endovascular treatment of cerebral pathologies.

XCath, an early-stage medical device company dedicated to expanding endovascular treatment modalities through its robotic systems and guidewires, took part in a panel last week at the first-ever Telesurgery Consensus Conference hosted by the Society of Robotic Surgery (SRS). The event, which took place in Orlando, Florida from February 3-4, provided a forum for international leaders in the surgical and robotic spaces to examine priorities and challenges in the ever-changing field of remote surgery.